Abstract: Bioavailability of Coenzyme-Q 10 (“Co-Q10”), an oil-soluble substance, can be enhanced in a subject by modifying, e.g. nanonizing or charging, the form of Co-Q10. Co-Q10 bioavailability also can be enhanced by administering Co-Q10 to the subject as an oil (lipid)-based and water (hydro)-based mixed composition, along with other optional components, such as oils, resins and other carriers. Accordingly, the invention provides various Co-Q10 compositions, e.g. compositions comprised of (i) Co-Q10 dissolved in one or more Co-Q10-soluble oils and (ii) Co-Q10 in admixture with at least one water-dispersible agent. A Co-Q10 complex of the invention, therefore, yields an increased cell absorption rate, as well as an enhanced percentage of Co-Q10 peak absorption, compared to previously known compounds. Methods for making and using the aforementioned compositions also are provided.

Abstract: A benzoquinone or hydroquinone for use in the topical treatment of a condition which is caused, exacerbated or transmitted by bacterial, in particular staphylococcal or propionibacterial, activity. The condition may be a skin or skin structure condition such as acne. The invention also provides the use of a benzo- or hydroquinone in the manufacture of a medicament for the treatment of such a condition.

Abstract: Use of idebenone for the preparation of a medicament for the treating of a muscular dystrophy in particular for treating and/or preventing weakness and/or loss of skeletal muscle tissue and/or cardiomyopathy associated with a muscular dystrophy.

Abstract: A composition comprising at least a therapeutically effective amount of L-carnitine fumarate, and an extract of Coleus forskohlii is provided to maintain androgen and androgen-like uptake potential in cells, via simultaneous increase in the availability of androgen receptors and improved availability of androgen and androgen-like molecules. A method of same is also provided. The present invention further comprises therapeutically effective amounts of one or more of N-acetyl L-carnitine, melatonin. ubidecarenone (coenzyme Q10), idebenone, decylubiquinone, an extract of Agaricus blazei Murill, and ginsenoside Rb1.

Abstract: A Phyto-nutraceutical composition for the prevention and treatment of hypertensive disorders is provided. A specific combination of extracts of plants and nutraceuticals is provided, based on categorizing plants and nutraceuticals into one of three groups, Energy, Bio-Intelligence, and Organization. Such combinations have synergistic effects, with minimal side effect.

Abstract: The present invention relates to a topical method of treatment for dysfunction of certain dermal enzymes, and the treatment of skin condition or disorder caused by said dysfunction. The said method of treatment consists of (i) an extra-cellular, matrix metalloprotease regulating agent, and (ii) an intra-cellular ubiquitin—proteasome regulating agent, and (iii) an epidermal melanocyte-regulating agent; and, wherein, said extra-cellular agent, said intracellular agent, and said epidermal agent can, surprisingly and unexpectedly, be a single multi-function compound having chemical formula (I).

Abstract: Systems and methods are provided herein that provide for promoting cellular health and treatment of cancer, and allied diseases such as diabetes and glaucoma.

Abstract: The present invention is directed to the use of a compound selected from the group consisting of ?-carotene, lutein, lycopene and ?-cryptoxanthin, and mixtures thereof and combinations thereof with CoQ-10 for maintaining the energy metabolism, the energy flow and/or the energy production in skin or of skin of animals including humans, for maintaining the respiratory function of the skin of animals including humans, for energizing the skin, maintaining and supporting the radiance and natural glow of the skin of animals including humans and for promoting a healthy appearance of the skin of animals including humans for preventing UV-A radiation-induced mtDNA mutagenesis in skin of animals including humans, as well as for the manufacture of a composition, preferably an orally applicable composition, for these uses and the corresponding methods.

Abstract: The present invention relates to a composition comprising paeonol of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient for inhibiting angiogenesis, or for enhancing radiosensitization. The present invention also relates to novel use of paeonol of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a composition for inhibiting angiogenesis, or for the manufacture of a composition for enhancing radiosensitization. Also, the present invention relates to a method for inhibiting angiogenesis which comprises administrating to a subject in need thereof an effective amount of paeonol of formula (I) or a pharmaceutically acceptable salt thereof, or a method for enhancing radiosensitization which comprises administrating an effective amount of paeonol of formula (I) or pharmaceutically acceptable salts thereof to a subject in need of radiotherapy.

Abstract: The combination of a polymyxin composition and a hop composition produces unexpected and synergistic activity against gram positive bacteria.

Abstract: A method of controlling target aquatic microorganism pest populations by exposing the target population to an effective amount of an aquacidal compound. The aquacidal compounds are selected from the group consisting of quinones, anthraquinones, naphthalenediones, quinine, warfarin, coumarins, amphotalide, cyclohexadiene-1,4-dione, phenidione, pirdone, sodium rhodizonate, apirulosin and thymoquinone. The method is particularly effective for treating ballast water of ships or other enclosed volumes of water subject to transport between or among geographic areas to control the relocation of plants, toxic bacteria, and animals contained in the water.

Abstract: The present disclosure describes a novel composition for the treatment and/or prevention of neurogenic inflammation. Such composition is also useful in the treatment and/or prevention of disease states and conditions associated with neurogenic inflammation. Such disease states and conditions include, but are not limited to, migraine headache, arthritis and fibromyalgia. The composition comprises nutrient compounds in a novel combination and formulation to treat and/or prevent neurogenic inflammation and disease states and conditions associated therewith. By reducing neurogenic inflammation, the compositions of the present disclosure reduce the symptoms associated with neurogenic inflammation, such as pain and systemic inflammation in general.

Abstract: A method of treating skin changes and conditions in human skin including applying a topical preparation that includes an active agent including probucol, a derivative of probucol or a combination of probucol and a derivative of probucol.

Abstract: The subject invention pertains to materials and methods for the prevention and treatment of gastrointestinal diseases, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Therapeutic compositions of the invention include compositions that can neutralize hydrogen peroxide, such as reducing agents and oxidizing agents. In one embodiment, a therapeutic composition of the invention comprises a reducing agent such as sodium thiosulfate. Therapeutic compositions of the invention can optionally include compounds with antibacterial activity, compositions that inhibit bacterial adherence to cells and tissue, compositions that inhibits epithelial lipid peroxidation, compositions that add viscosity to a solution, compositions that inhibit most cells, and/or compositions that help to seal or repair tight junctions between cells of the colonic epithelium of the gastrointestinal tract. Methods of the invention include administration of compounds or compositions of the invention.

Abstract: The present invention pertains to compounds of the following formula: (1) wherein: RALK is primary or secondary aliphatic saturated C2-6alkyl; each of RB2, RB3, RB4, and RB5 is independently —H, —OH, or —OMe; each of R1 and R2 is independently: —H, optionally substituted C1-4alkyl, or optionally substituted C5-20aryl; RA3 is —H, —OH, —OC(?O)RE, —OS(?O)2OH, or —OP(?O)(OH)2; RE is: —H, optionally substituted C1-6alkyl, optionally substituted C3-20heterocyclyl, or optionally substituted C5-20aryl; or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof.

Abstract: A NF-?B inhibitor represented by the following formula (I) is provided: ?

Abstract: The present invention relates to a synergistic hepatoprotective pharmaceutical composition comprising an effective amount of trans-tetracos-15-enoic acid (TCA) and Apocynin (APO), the present invention also relates to a method of treatment for hepatotoxicity in mammals and humans.

Abstract: Novel and known trifluoroacetyl-substituted phenyl, phenol and benzoyl compounds for the treatment and/or inhibition of obesity and of concomitant and/or secondary diseases involved therewith, in particular metabolic syndrome and cardiovascular diseases. Novel trifluoroacetyl-substituted phenyl, phenol and benzoyl compounds, pharmaceutical preparations containing them and processes for the preparation of these compounds. Also compounds acting as inhibitors of lipase, in particular pancreatic lipase.

Abstract: The present invention concerns alkyl aryl carbonyl compounds that possess anti-infective activity. The compounds of the invention can be used to target specific nuclear localization signal, thereby blocking importation of specific proteins or molecular complex into the nucleus of a cell. The invention encompasses methods of use of such compounds for treatment or prevention of infectious diseases, such as parasitic and viral diseases, including, for example, malaria and acquired immunodeficiency syndrome. The use of the compounds to detect certain specific protein structures which are present in nuclear localization sequences is also taught.

Abstract: The use of L-carnitine and its alkanoyl devivatives, optionally in the form of a pharmaceutically acceptable salt, as osmotic agents in the preparation of solutions for medical use, particularly for peritoneal dialysis, is described.

Abstract: The present invention provides an MMP-inhibitory composition comprising chalcone or its derivatives. They inhibit the MMPs in collagenase subfamily as well as those in gelatinase subfamily. The MMP inhibitory activity of chalcone derivatives was similar to or greater than that of parent compound, chalcone. Chalcone or its derivatives of the present invention inhibit activity of matrix metalloproteinase, so that it can be applied to treat and prevent diseases related to matrix metalloproteinase.

Abstract: The use of a pharmaceutical formulation in treating coronary arteriosclerosis and a two-component pharmaceutical formulation. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimithyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone.

Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A&bgr; amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Abstract: The use of benzophenones of the formula I 1

Abstract: A composition including (a) a Platelet Activating Factor (PAF) Inhibitor and (b) an antioxidant which interferes with the arachidonic acid cascade and also has antioxidant activity. The compositions are useful for the treatment or the relief of inflammatory disease, thrombosis, cardiac problems, and/or conditions caused by platelet induced blood clotting.

Abstract: The invention relates to non-peptidic compounds that possess bioactive properties, such as the ability to protect neuronal cells from otherwise lethal treatments or the ability to promote the growth or regeneration of neuronal cells. In part, the invention provides compounds that interact with or bind to a cyclophilin and compounds that have activity towards neuronal cells. Methods for using the compounds, such as administering them to cells or animals or using them to treat neurodegenerative conditions, are specifically included.

Abstract: Methods of inhibiting angiogenesis, endothelial cell migration or endothelial cell proliferation, by inhibiting NADPH oxidase inhibitors, production of reactive oxygen species, or by inhibition of mRNA induction of superoxide dismutase (e.g., mitochondrial SOD), are described herein.

Abstract: The present invention relates to an oral compacted composition comprising entacapone, nitecapone, or a pharmaceutically acceptable salt thereof and croscarmellose sodium. The composition is premised on the discovery that croscarmellose sodium increases the release rate of entacapone or nitecapone from an oral compacted composition. Preferably the amount of croscarmellose sodium in the composition is at least 6% by weight, preferably from about 8% to about 16% by weight, especially from about 10% to about 14% by weight.

Abstract: The invention relates to compounds of formula I and of formula II in which R1, R2, R3, R4, R5, X1, X2, X3, X4, X5 and Y are defined in the specification. The compounds of formulae I and II inhibit cyclin-dependent kinases (CDKS) and other kinases (KDR), have cytostatic actions, and are suitable for treating tumors. The compounds of formulae I and II are obtainable by extracting the plant Uvaria klaineri, PLA 100484, by cell cultures of the plant Uvaria klaineri, or by chemical synthesis. The invention relates to a method for preparing the compounds of formulae I and II, to the use of the compounds for producing a pharmaceutical for the treatment of malignant disorders and of diseases which may be treated by inhibition of CDKs and KDR, and also to pharmaceutical compositions comprising at least one compound of the formula I or II.

Abstract: Compositions and methods are provided for prevention and treatment of cancer. The compositions comprise pure hydroxylated chalcone compounds of licorice root (Glycyrrhiza glabra) including 1-propanone-1-(2,4-dihydroxyphenyl)-3-hydroxy-3-(4′-hydroxyphenyl).

Abstract: The invention relates to a novel class of compounds that have structures related to certain naturally occurring or synthetic chalcones. The invention also relates to pharmaceutical compositions comprising the compounds and methods for treating certain disorders using the pharmaceutical compositions. The invention further relates to a process for synthesizing the novel class of compounds.

Abstract: Compositions containing as active ingredients a lipid-soluble benzoquinone, e.g. Coenzyme Q10 and at least one omega-3 polyunsaturated fatty acid selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and linolenic acid (LNA), for the prevention and/or treatment of mitochondriopathies.

Abstract: A method of increasing the volume, the total sperm count and the reproductive performance of semen from human and animal males, is described. The method comprises administration of an effective dosage of a human or veterinary preparation containing at least one type of xanthoplylls, such as astaxanthin, to said males. Preferably, the astaxanthin exists in a form esterified with fatty acids, e.g. in the form of algal meal produced by culturing of the alga Haematococcus sp. Further, the use of at least one type of xanthophylls, such as astaxanthin, for the preparation of a human or veterinary preparation for increasing the volume, the total sperm count and the reproductive performance of semen from human and animal males, is disclosed.

Abstract: This invention relates to the isolation of a novel putative efflux gene from Pseudomonas mendocina. The putative efflux gene is useful for probing an organism's efflux system to gain an understanding of the mechanisms of solvent tolerance. The invention further provides a Pseudomonas mendocina strain deficient in this gene. This strain is unable to grow in the presence of chloramphenicol and, compared to the wildtype strain, grows slowly in the presence of high concentrations of PHBA.

Abstract: The invention is organic pesticides made from components of hop extract by preparing stable aqueous emulsions of hop acids and other hop extract components. The hop acids and other hop extract components are suspended as stable, colloidal preparations in water, which can be sprayed directly on plants for pest control.

Abstract: Disclosed herein are methods to treat cognition disorders, particularly those associated with aging. The method comprises administering a combination of a carnitine and an oxidant. Preferably the oxidant is thioctic acid. Preferably 0.12 grams to 3 grams of carnitine (particularly ALC) and 0.12 and 1.5 grams of R-&agr;-lipoic acid are administered. Optionally, coenzyme Q and/or creatine also are administered. Preferably 10 mg to 500 mg/day of coenzyme Q10 and 1 to 30 grams/day of creatine are administered. The same method can be used to treat cognition deficits associated with carbon monoxide poisoning, mild traumatic brain injury, Type 2 diabetes mellitus, obsessive-compulsive disorder, environmental toxin exposure, and other conditions.

Abstract: A projectile can be used to administer pesticides such as one or more from the group consisting of 4-allylanisole, anisole, allylbenzene, 4-isopropylanisole, p-anisaldehyde, ethylbenzene, cumene, 4-methoxyacetophenone, 4-methylstyrene, 2-propylphenol, phenetole, and toluene, for scolytid infestation. Conifers, which are a target for scolytids, are protected by the application of the pesticides by use of a projectile containing the compound which explodes upon contact with the conifer thereby emitting the compound.

Abstract: The present invention relates to ketone derivatives represented by the following formula and medical agents containing the ketone derivatives or pharmacologically acceptable salts thereof as an active ingredient, and in particular, relates to a hematopoietic agent; it is shown that the present invention increases blood cells, such as platelets, white blood cells, and red blood cells, and is effective in preventing and treating cytopenia caused by cancer chemotherapy, radiation therapy, and the like.

Abstract: A method of treating or preventing a disorder resulting from a mitochondr dysfunction induced by an iron overload including Friedreich Ataxia, hypertrophic cardiomyopathy, Hallervorden-Spatz disease, sideroblastic anemia by administering an effective amount of an ubiquinone derivative such as idebenone, decylubiquiqnone, coenzyme Q2, coenzyme Q4, and coenzyme Q6, either alone or in conjunction with a second therapeutic agent or a non-reducing antioxidant.

Abstract: The pharmaceutical compositions including a slightly soluble drug incorporated in a water-swellable, but water-insoluble cross-linked polymer, a surface active agent, and an oil show much improved dissolution and, consequently, bioavailability in respect of the drug as is or used with a polymeric carrier of said type.

Abstract: The present invention is directed to a method for the prophylactic and therapeutic treatment of reperfusion injury or injury due to a distal reperfusion. The method involves the administration of an NADPH-oxidase inhibitor to a cell, tissue, organ or animal in an amount sufficient to treat the cell, tissue, organ or animal for reperfusion injury prophylactically or therapeutically. The NADPH-oxidase inhibitor preferably is an o-methoxycatechol, or a pharmaceutically acceptable salt, derivative, dimer or prodrug thereof. Most preferably, the o-methoxycatechol is apocynin.

Abstract: A method for the reduction in the risk of transmitting a sexually transmitted disease--especially HIV and/or HSV--during sexual activity is provided. This method generally comprises the application of an effective amount of an inhibitory agent, preferably as a topical formulation, to the area or areas of sexual contact prior to engaging in sexual activity. Inhibitory agents which are useful in the present invention include, for example, phosphorylated hesperidins, sulfonated hesperidins, polystyrene sulfonates, substituted benzenesulfonic acid formaldehyde co-polymers, H.sub.2 SO.sub.4 -modified mandelic acids, and the like. This method can be used by heterosexuals, homosexuals, and/or bisexuals engaged in a wide variety of sexual activities. In addition to anti-STD activity, these agents may also act as vaginal contraceptives; moreover, they generally have fewer side effects than conventional vaginal contraceptives (e.g., nonoxynol-9).

Abstract: A combination can be of L-carnitine and acetyl-L-carnitine, preferably with pantothenic acid or ubiquinone, is administered orally or as a parenteral injection in domesticated animals, especially pet animals, and humans for prevention or treatment of syndromes or diseases arising from dysfunctional energy metabolism. Syndromes involving skeletal and cardiac muscle benefited from L-carnitine, and syndromes related to the central nervous system improved with acetyl-L-carnitine, are effectively treated. The cofactors L-carnitine and acetyl-L-carnitine do not substitute metabolically for each other, and the effects of the combination are found to be synergistic.

Abstract: A method for the prevention and treatment of atherosclerosis and its related diseases in mammals, in which an NADPH oxidase inhibitor is administered, is provided. The NADPH oxidase inhibitor prevents the production of reactive oxygen species upon exposure of endothelial cells to atherogenic LDL levels, thus resulting in decreased endocytosis and vascular hyperpermeability. Preferred NADPH oxidase inhibitors are of the formula: ##STR1## Additionally, there is provided a diagnostic method for predicting risk of a human patient to atherosclerotic-related diseases.

Abstract: A method for the prevention and treatment of atherosclerosis and its related diseases in mammals is provided, in which an NADPH oxidase inhibitor is administered to mammals. The NADPH oxidase inhibitor prevents the production of reactive oxygen species upon exposure of endothelial cells to atherogenic LDL levels, resulting in decreased endocytosis and vascular hyperpermeability. Apocynin is a preferred NADPH oxidase inhibitor. Additionally, there is provided a diagnostic method for predicting the risk to an individual of atherosclerotic-related diseases.

Abstract: Compositions for controlling the growth of microorganisms in or on a product, material or medium comprising synergistically effective amounts of halogenated acetophenones, such as 2-bromo-4-hydroxyacetophenone, and at least one organic acid, its salt or ester are disclosed. Methods to control the growth of microorganisms and prevent spoilage caused by microorganisms with the use of the compositions of the present invention are also disclosed.

Abstract: Diaromatic compounds, characterised in that they correspond to the following general formula: ##STR1## in which: R.sub.1 is --CH.sub.3, --CH.sub.2 OH, --COR.sub.8 or --CH.sub.2 OCOR.sub.9, R.sub.8 is H, OH, --OR.sub.10, --N(rr') or alkyl, R.sub.10 is alkyl, alkenyl, aryl or aralkyl, r and r' being H, alkyl, aryl, aralkyl, etc., r and r' together form a heterocycle, R.sub.9 is alkyl, alkenyl or a sugar residue, R.sub.2 and R.sub.3 are --OR.sub.11 or --OCOR.sub.11, R.sub.11 is H, alkyl, fluoroalkyl, aryl or aralkyl, R.sub.3 in addition being H, R.sub.4 is H, OH, alkyl, alkoxy, F, Cl or --CF.sub.3, R.sub.5 and R.sub.7 are H, OH, alkoxy, .alpha.-substituted alkyl or .alpha.,.alpha.'-disubstituted alkyl, etc., R.sub.6 is H, OH, alkyl, alkoxy, cycloalkyl, etc., R.sub.5 and R.sub.7 cannot simultaneously be OH or alkoxy and R.sub.4, R.sub.5, R.sub.6 and R.sub.7 cannot simultaneously be H, R.sub.5 and R.sub.6 or R.sub.6 and R.sub.

Abstract: Compositions for controlling the growth of microorganisms in or on a product, material or medium comprising synergistically effective amounts of halogenated acetophenones, such as 2-bromo-4-hydroxyacetophenone, and at least one organic acid, its salt or ester are disclosed. Methods to control the growth of microorganisms and prevent spoilage caused by microorganisms with the use of the compositions of the present invention are also disclosed.

Abstract: The present invention relates to pyrrole compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, in particular as anti-psychotic agents.

Abstract: Compositions for controlling the growth of microorganisms in or on a product, material or medium comprising synergistically effective amounts of halogenated acetophenones, such as 2-bromo-4-hydroxyacetophenone, and at least one organic acid, its salt or ester are disclosed. Methods to control the growth of microorganisms and prevent spoilage caused by microorganisms with the use of the compositions of the present invention are also disclosed.